|Day Low/High||11.22 / 11.83|
|52 Wk Low/High||8.88 / 21.64|
I'll be watching for entry points to develop this afternoon.
The best way to deal with the struggling market is selective stock picking and good defense.
I think we'll probably see some shifting in the tariff policy over the weekend, giving the market some relief.
It is very easy to force trades in this sort of environment.
If we have a little consolidating action here the buyers will start pushing again.
There are signs of stabilization, but the market is still digesting some very big swings.
The big question right now is to what degree should you be looking to take positions in individual stocks you may like.
These names are displaying bullish and bearish reversal patters over the last week.
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
It would be better from a trading standpoint for this market to sell off with some vigor.
"Cara Mia why must we say goodbye? Each time we part my heart wants to die Darling hear my prayer Cara Mia fair I'll be your love till the end of time..." --Jay and the Americans, "Cara Mia" I want to call everyone's attention to our Comments S...
Some minor improvement in the major indices from our last update. Market is almost to flat line as we approach the close of the week -- and June options expiration, as well. Whole Foods Market is slightly above the $42 a share buyout offer from Ama...
At stake is whether the Republicans can work out their differences.
After yesterday's surprise pullback, this is the sort of consolidation we need.
Readers want to know what to do with the two biotech names, which are headed in opposite directions.
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst
The market is extremely flat today as we hit midday. Equities are about as exciting right now as the Rams offense was just hours ago on Thursday Night Football. Two of my favorite small biopharma names, Egalet and Cara Therapeutics , are on the way...
There simply aren't many compelling trades on my screen.
Not much change in the market since our last update. The S&P 500 and Dow are down, and the NASDAQ is having a nice day. Longtime favorite Cara Therapeutics continues its huge run, up another 20% plus today. But I can't find any new news to support t...
And we are off. The market has opened opens slightly lower across the board. We're seeing some profit taking early on in stocks and sectors that have done extremely well since the election. United Rentals , after massive run over the past week, is d...